Table 1.
Potential neoantigens derived from various genetic variations for AML
| Gene name | Mutated position | neopeptide | HLA restriction | References |
|---|---|---|---|---|
| Gene fusion | ||||
| CBFB-MYH11 | / | REEMEVHEL | B*40:01 | [53] |
| PML-RARA | / | NSNHVASGAGEAAIETQSSSSEEIV | DR*11 | [56] |
| DEK-CAN | / | TMKQICKKEIRRLHQY | DR*53; DR*9 | [101] |
| Indels | ||||
| NPM1 | 283–291 | AIQDLCLAV | A*02:01 | [18, 20] |
| 283–291 | AIQDLCVAV | A*02:01 | [18, 20] | |
| 289–297 | LAVEEVSLR | A*02:01 | [61] | |
| 290–298 | AVEEVSLRK | A*02:01 | [61] | |
| 288–296 | CLAVEEVSL | A*02:01 | [62] | |
| FLT3-ITD | / | YVDFREYEYY | A*01:01 | [68] |
| Non-synonymous point mutations | ||||
| IDH1 | R132H | GWVKPIIIGHHAYGDQYRAT | DRB1*0101 | [74] |
| KRAS | G12D | GADGVGKSA | C*08:02 | [83] |
| G12D | GADGVGKSAL | C*08:02 | [83] | |
| G12D | VVVGADGVGK | A*11:01 | [102] | |
| G12V | VVVGAVGVGK | A*11:01 | [102] | |
| TP53 | R175H | HMTEVVRHC | A*02:01 | [89, 94] |
| R175H | YKQSQHMTEVVRHCPHHERCSDSDG | Class II | [89] | |
| R175H | VVRHCPHHERCSDSD | DRB1*13:01 | [89] | |
| R175H | QHMTEVVRHCPHHER | DRB1*13:01 | [89] | |
| Y220C | RNTFRHSVVVPCE | DRB1*04:01 | [89] | |
| Y220C | VVPCEPPEV | A*02:01 | [89] | |
| Y220C | NTFRHSVVVPCEPPE | DRB3*02:02 | [89] | |
| G245S | HYNYMCNSSCMGSMN | DRB3*02:02 | [89] | |
| R248Q | YMCNSSCMGGMNQRPILTIITLEDS | Class I and II | [89] | |
| R248W | SSCMGGMNWR | A*68:01 | [89] | |
| R248W | SCMGGMNWRPILTII | DRB1*02:01 | [89] | |
| R248W | FEVRVCACPGRDWRTEEENLRKKGE | Class II | [89] | |
| G245S | HYNYMCNSSCMGSMN | DRB3*02:02:01 | [90] | |
| Y220C | NTFRHSVVVPCEPPE | DRB3*02:02:01 | [90] | |
| P190L | ALPQHLIRV | A*0201 | [91] | |
| R267P | LLGPNSFEV | A*0201 | [91] | |
| A161T | RVRAMTIYKQ | A*1101 | [93] | |
| Splicing variants | ||||
| SF3B1 | R625C/H/L/S | LLIRWQHFL | A*0201 | [99] |
| AALPILFQV | A*0201 | [99] | ||
| ALLLQLFTL | A*0201 | [99] | ||
| ALLPGLPAA | A*0201 | [99] | ||
| RLPGVLPRA | A*0201 | [99] | ||